CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells
Authors
M N A Bijman
A Calogero
+6 more
L Delahaye
M W A de Jonge
B J Kroesen
L de Leij
A J Stel
S Withoff
Publication date
20 April 2001
Publisher
Nature Publishing Group
Doi
Cite
View
on
PubMed
Abstract
This paper describes a bi-specific antibody, which was called BIS20x3. It retargets CD3ɛ-positive cells (T-cells) to CD20-positive cells and was obtained by hybrid–hybridoma fusion. BIS20x3 could be isolated readily from quadroma culture supernatant and retained all the signalling characteristics associated with both of its chains. Cross-linking of BIS20x3 on Ramos cells leads to DNA fragmentation percentages similar to those obtained after Rituximab-cross-linking. Cross-linking of BIS20x3 on T-cells using cross-linking F(ab′)2-fragments induced T-cell activation. Indirect cross-linking of T-cell-bound BIS20x3 via Ramos cells hyper-activated the T-cells. Furthermore, it was demonstrated that BIS20x3 effectively re-targets T-cells to B-cells, leading to high B-cell cytotoxicity. The results presented in this paper show that BIS20x3 is fully functional in retargeting T-cells to B-cells and suggest that B-cell lymphomas may represent ideal targets for T-cell retargeting bi-specific antibodies, because the retargeted T-cell is maximally stimulated in the presence of B-cells. Additionally, since B-cells may up-regulate CD95/ Fas expression upon binding of CD20-directed antibodies, B-cells will become even more sensitive for T-cell mediated killing via CD95L/ Fas L, and therefore supports the intention to use T-cell retargeting bi-specific antibodies recognizing CD20 on B-cell malignancies as a treatment modality for these diseases. © 2001 Cancer Research Campaign http://www.bjcancer.co
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:publications/c...
Last time updated on 29/10/2019
ARTS repository - University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:publications/c...
Last time updated on 03/06/2022
Proceedings - University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:publications/c...
Last time updated on 01/06/2022
University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:openaire_cris_...
Last time updated on 22/04/2023
Dissertations of the University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:publications/c...
Last time updated on 02/06/2022
NARCIS
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 15/10/2017
University of Groningen Research Database
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:publications/c...
Last time updated on 10/02/2018
Dissertations of the University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:openaire_cris_...
Last time updated on 22/04/2023
Proceedings - University of Groningen
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.rug.nl:openaire_cris_...
Last time updated on 22/04/2023